Lower prices are unlocking the next leg of GLP-1 growth

Several years ago, the bullish case for GLP-1 penetration hinged on lower pricing and the availability of oral options-both of these have materialized over the past 18 months. Yet we remain early in the oral GLP-1 ramp, and pricing continues to adjust downward, suggesting ample runway for unit growth in these weight-loss therapies. Peter Galbo discusses the impact on food and beverage we've observed at today's ~10% penetration levels and what may lie ahead, especially as Jason Gerberry outlines where penetration could ultimately land and the improvements expected in side-effect profiles. We also examine intensifying competition within the GLP-1 landscape, as well as the packaged food and beverage segments most at risk-or best positioned to benefit-alongside areas where potential upside may be overstated

You may also enjoy listening to the Merrill Perspectives podcast, featuring conversations on the big stories, news and trends affecting your everyday financial life.

"Bank of America" and “BofA Securities” are the marketing names for the global banking businesses and global markets businesses (which includes BofA Global Research) of Bank of America Corporation. Lending, derivatives, and other commercial banking activities are performed globally by banking affiliates of Bank of America Corporation, including Bank of America, N.A., Member FDIC. Securities, trading, research, strategic advisory, and other investment banking and markets activities are performed globally by affiliates of Bank of America Corporation, including, in the United States, BofA Securities, Inc. a registered broker-dealer and Member of FINRA and SIPC, and, in other jurisdictions, by locally registered entities. ©2026 Bank of America Corporation. All rights reserved.

GLP-1s are shrinking some appetites; broader use poses a prickly challenge

Global Research Unlocked

GLP-1s are shrinking some appetites; broader use poses a prickly challenge